References
- Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010. Epub 2018/03/16. doi: https://doi.org/10.1038/nrdp.2018.10. Epub 2018/03/16.
- Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142–151. doi:https://doi.org/10.1016/S0140-6736(12)61229-X Epub 2012/10/30. doi: . PubMed PMID: 23103089; PubMed Central PMCID: PMC3547249
- Piel FB, Patil AP, Howes RE, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1(1):104. doi:https://doi.org/10.1038/ncomms1104 Epub 2010/11/04. doi: . PubMed PMID: 21045822; PubMed Central PMCID: PMC3060623
- Mangla A, Ehsan M, Agarwal N, et al. Sickle Cell Anemia. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021; PMID: 29489205.
- Grosse SD, Odame I, Atrash HK, et al. Sickle cell disease in Africa: a neglected cause of early childhood mortality.Am J Prev Med.2011;41(6 Suppl 4):S398–405; Epub 2011/12/07. doi: https://doi.org/10.1016/j.amepre.2011.09.013. PubMed PMID: 22099364; PubMed Central PMCID: PMC3708126;
- Rees DC, Brousse VA. Sickle cell disease: status with particular reference to India.Indian J Med Res.2016;143(6):675–677; Epub 2016/10/18. doi: https://doi.org/10.4103/0971-5916.191916. PubMed PMID: 27748289; PubMed Central PMCID: PMC5094104;
- Rankine-Mullings AE, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev. 2017;10. CD003427. Epub 2017/10/11. doi: https://doi.org/10.1002/14651858.CD003427.pub4. PubMed PMID: 28994899; PubMed Central PMCID: PMC6485662. doi:
- Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314(25):1593–1599. doi: https://doi.org/10.1056/NEJM198606193142501. Epub 1986/06/19. doi: . PubMed PMID: 3086721
- Kolata G. Panel urges newborn sickle cell screening: gale academic onefile. Science. 1987;236(4799):259–60. doi:https://doi.org/10.1126/science.3563504
- Conference C. Consensus conference. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA. 1987;258(9):1205–1209. Epub 1987/09/04. PubMed PMID: 3626004.
- Benson JM, Therrell BL Jr. History and current status of newborn screening for hemoglobinopathies.Semin Perinatol.2010;34(2):134–144; Epub 2010/03/09. doi: https://doi.org/10.1053/j.semperi.2009.12.006. PubMed PMID: 20207263;
- Therrell BL Jr., Lloyd-Puryear MA, Eckman JR, et al. Newborn screening for sickle cell diseases in the United States: a review of data spanning 2 decades.Semin Perinatol.2015;39(3):238–251; Epub 2015/05/17. doi: https://doi.org/10.1053/j.semperi.2015.03.008. PubMed PMID: 25979783;
- Lobitz S, Telfer P, Cela E, et al. Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. Br J Haematol. 2018;183(4):648–660. doi:https://doi.org/10.1111/bjh.15600 Epub 2018/10/20. doi: . PubMed PMID: 30334577
- Institute for Quality and Efficiency in Health Care (IQWiG). Newborn screening for sickle cell disease (SCD): IQWiG Reports – Commission No. S18-01 [Internet]. Institute for Quality and Efficiency in Health Care: Extracts. Cologne (Germany): Institute for Quality and Efficiency in Health Care (IQWiG); 2019. PMID: 31820891
- ZS MMD, Rogers ZR, Buchanan GR, et al. Survival into adulthood in sickle cell disease from the Dallas newborn cohort. Blood. 2014;124(21):599. DOI: https://doi.org/10.1182/BLOOD.V124.21.559.559
- Piel FB, Hay SI, Gupta S, et al. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions.PLoS Med.2013;10(7):e1001484; Epub 2013/07/23. doi: https://doi.org/10.1371/journal.pmed.1001484. PubMed PMID: 23874164; PubMed Central PMCID: PMC3712914;
- Diallo D, Tchernia G. Sickle cell disease in Africa. Curr Opin Hematol. 2002;9(2):111–116; Epub 2002/02/15. doi: https://doi.org/10.1097/00062752-200203000-00005. PubMed PMID: 11844993;
- Hsu L, Nnodu OE, Brown BJ, et al. White paper: pathways to progress in newborn screening for sickle cell disease in Sub-Saharan Africa. J Trop Dis Public Health. 2018;6(2):260. doi:https://doi.org/10.4172/2329-891X.1000260 Epub 2018/12/07. doi: . PubMed PMID: 30505949; PubMed Central PMCID: PMC6261323
- Segbefia CI, Goka B, Welbeck J, et al. Implementing newborn screening for sickle cell disease in Korle Bu Teaching Hospital, Accra: results and lessons learned. Pediatr Blood Cancer. 2021;68(7):e29068. doi:https://doi.org/10.1002/pbc.29068 Epub 2021/04/24. doi: . PubMed PMID: 33890391
- Boemer F, Ketelslegers O, Minon JM, et al. Newborn screening for sickle cell disease using tandem mass spectrometry.Clin Chem.2008;54(12):2036–2041; Epub 2008/10/04. doi: https://doi.org/10.1373/clinchem.2008.106369. PubMed PMID: 18832473;
- Frommel C. Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies: a Short Review on Classical Laboratory Methods-Isoelectric Focusing, HPLC, and Capillary Electrophoresis. Int J Neonatal Screen. 2018;4(4):39; Epub 2018/12/05. doi: https://doi.org/10.3390/ijns4040039. PubMed PMID: 33072959; PubMed Central PMCID: PMC7548892;
- Padilla CD, Krotoski D, Therrell BL Jr. Newborn screening progress in developing countries–overcoming internal barriers. Semin Perinatol. 2010;34(2):145–155; Epub 2010/03/09. doi: https://doi.org/10.1053/j.semperi.2009.12.007. PubMed PMID: 20207264;
- Obaro SK, Daniel Y, Lawson JO, et al. Sickle-Cell Disease in Nigerian Children: parental Knowledge and Laboratory Results. Public Health Genomics. 2016;19(2):102–107. doi:https://doi.org/10.1159/000444475 Epub 2016/03/19. doi: . PubMed PMID: 26991896
- Marsh VM, Kamuya DM, Molyneux SS. ‘All her children are born that way’: gendered experiences of stigma in families affected by sickle cell disorder in rural Kenya. Ethn Health. 2011;16(4–5):343–359; Epub 2011/07/30. doi: https://doi.org/10.1080/13557858.2010.541903. PubMed PMID: 21797722; PubMed Central PMCID: PMC3534410;
- Brinda EM, Rajkumar AP, Enemark U. Association between gender inequality index and child mortality rates: a cross-national study of 138 countries. BMC Public Health. 2015;15(1):97; Epub 2015/04/18. doi: https://doi.org/10.1186/s12889-015-1449-3. PubMed PMID: 25886485; PubMed Central PMCID: PMC4353466;
- Zhong A, Darren B, Loiseau B, et al. Ethical, social, and cultural issues related to clinical genetic testing and counseling in low- and middle-income countries: a systematic review. Genet Med. 2018;23(12):2270–2280. doi:https://doi.org/10.1038/s41436-018-0090-9 Epub 2018/08/04. doi: . PubMed PMID: 30072741
- Saadallah AA, Rashed MS. Newborn screening: experiences in the Middle East and North Africa. J Inherit Metab Dis. 2007;30(4):482–489; Epub 2007/08/19. doi: https://doi.org/10.1007/s10545-007-0660-5. PubMed PMID: 17701444;
- Weber AM, Cislaghi B, Meausoone V, et al. Gender norms and health: insights from global survey data. Lancet. 2019;393(10189):2455–2468. doi:https://doi.org/10.1016/S0140-6736(19)30765-2 Epub 2019/06/04. doi: . PubMed PMID: 31155273
- Jain DL, Sarathi V, Upadhye D, et al. Newborn screening shows a high incidence of sickle cell anemia in Central India. Hemoglobin. 2012;36(4):316–322. doi:https://doi.org/10.3109/03630269.2012.691434 Epub 2012/06/21. doi: . PubMed PMID: 22712682
- McGann PT, Ferris MG, Ramamurthy U, et al. A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. Am J Hematol. 2013;88(12):984–989. doi:https://doi.org/10.1002/ajh.23578 Epub 2013/09/17. doi: . PubMed PMID: 24038490
- Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the expanded programme on immunization in Africa: looking beyond 2015.PLoS Med.2013;10(3):e1001405; Epub 2013/03/26. doi: https://doi.org/10.1371/journal.pmed.1001405. PubMed PMID: 23526886; PubMed Central PMCID: PMC3601964
- Ventola CL. Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations. P T. 2016;41(7):426–436. Epub 2016/07/14. PubMed PMID: 27408519; PubMed Central PMCID: PMC4927017.
- Reid SD, Fidler SJ, Cooke GS. Tracking the progress of HIV: the impact of point-of-care tests on antiretroviral therapy. Clin Epidemiol. 2013;5:387–396. Epub 2013/10/15. doi: https://doi.org/10.2147/CLEP.S37069. PubMed PMID: 24124392; PubMed Central PMCID: PMC3794838.
- Alvarez OA, Hustace T, Voltaire M, et al. Newborn screening for sickle cell disease using point-of-care testing in low-income setting. Pediatrics. 2019;144(4). doi:https://doi.org/10.1542/peds.2018-4105 Epub 2019/09/19. doi: . PubMed PMID: 31530717
- Ilyas S, Simonson AE, Asghar W. Emerging point-of-care technologies for sickle cell disease diagnostics. Clin Chim Acta. 2020;501:85–91. Epub 2019/11/05. doi: https://doi.org/10.1016/j.cca.2019.10.025. PubMed PMID: 31678569.
- Nnodu OE, Sopekan A, Nnebe-Agumadu U, et al. Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study. Lancet Haematol. 2020;7(7):e534–e40. doi:https://doi.org/10.1016/S2352-3026(20)30143-5 Epub 2020/06/27. doi: . PubMed PMID: 32589979; PubMed Central PMCID: PMC7322555
- Chawla SS, Gupta S, Onchiri FM, et al. Water availability at hospitals in low- and middle-income countries: implications for improving access to safe surgical care.J Surg Res.2016;205(1):169–178; Epub 2016/09/14. doi: https://doi.org/10.1016/j.jss.2016.06.040. PubMed PMID: 27621015;
- Hand T, Rosseau NA, Stiles CE, et al. The global role, impact, and limitations of Community Health Workers (CHWs) in breast cancer screening: a scoping review and recommendations to promote health equity for all. Glob Health Action. 2021;14(1):1883336. doi:https://doi.org/10.1080/16549716.2021.1883336 Epub 2021/04/27. doi: . PubMed PMID: 33899695; PubMed Central PMCID: PMC8079044
- PR KAK, Chami T, Hejjaji V, et al. The effectiveness of community health workers for CVD prevention in LMIC. Glob Heart. 2017;12(3):233–43 e6.
- Jalloh MF, Wilhelm E, Abad N, et al. Mobilize to vaccinate: lessons learned from social mobilization for immunization in low and middle-income countries.Hum Vaccin Immunother.2020;16(5):1208–1214; Epub 2019/08/30. doi: https://doi.org/10.1080/21645515.2019.1661206. PubMed PMID: 31464551; PubMed Central PMCID: PMC7227704;
- William BM, Corazza GR. Hyposplenism: a comprehensive review. Part I: basic concepts and causes.Hematology.2007;12(1):1–13; Epub 2007/03/17. doi: https://doi.org/10.1080/10245330600938422. PubMed PMID: 17364987;
- Salawu LOE, Durosinmi MA. Immunohaematological characteristics of Nigerian sickle cell disease patients in asymptomatic steady state. Eur J Gen Med. 2009;6:170–174.
- Falcao RP, Donadi EA. Infection and immunity in sickle cell disease. AMB Rev Assoc Med Bras. 1989;35(2):70–74. Epub 1989/03/01. PubMed PMID: 2695986.
- Overturf GD. Infections and immunizations of children with sickle cell disease. Adv Pediatr Infect Dis. 1999;14:191–218. Epub 1999/03/18. PubMed PMID: 10079855.
- Bunn HF, Epstein FH. Pathogenesis and treatment of sickle cell disease.N Engl J Med.1997;337(11):762–769; Epub 1997/09/11. doi: https://doi.org/10.1056/NEJM199709113371107. PubMed PMID: 9287233;
- Zhang D, Xu C, Manwani D, et al. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.Blood.2016;127(7):801–809; Epub 2016/01/14. doi: https://doi.org/10.1182/blood-2015-09-618538. PubMed PMID: 26758915; PubMed Central PMCID: PMC4760086;
- Dieye TN, Ndiaye O, Ndiaye AB, et al. Complement and serum immunoglobulins in homozygous and heterozygous sickle cell anemia in Senegal. Dakar Med. 1999;44(2):175–179. Epub 2002/04/18. PubMed PMID: 11957280.
- Blacksin MF, Finzel KC, Benevenia J. Osteomyelitis originating in and around bone infarcts: giant sequestrum phenomena. AJR Am J Roentgenol. 2001;176(2):387–391; Epub 2001/02/13. doi: https://doi.org/10.2214/ajr.176.2.1760387. PubMed PMID: 11159079;
- Elbashier AM, Al-Salem AH, Aljama A. Salmonella as a causative organism of various infections in patients with sickle cell disease. Ann Saudi Med. 2003;23(6):358–362; Epub 2006/07/27. doi: https://doi.org/10.5144/0256-4947.2003.358. PubMed PMID: 16868368;
- Bhutta ZA, Sommerfeld J, Lassi ZS, et al. Global burden, distribution, and interventions for infectious diseases of poverty.Infect Dis Poverty.2014;3(1):21; Epub 2014/08/12. doi: https://doi.org/10.1186/2049-9957-3-21. PubMed PMID: 25110585; PubMed Central PMCID: PMC4126350;
- Evans C, Orf K, Horvath E, et al. Impairment of neutrophil oxidative burst in children with sickle cell disease is associated with heme oxygenase-1. Haematologica. 2015;100(12):1508–1516. doi:https://doi.org/10.3324/haematol.2015.128777 Epub 2015/09/01. doi: . PubMed PMID: 26315932; PubMed Central PMCID: PMC4666326
- Ochocinski D, Dalal M, Black LV, et al. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Front Pediatr. 2020;8:38. Epub 2020/03/11. doi: https://doi.org/10.3389/fped.2020.00038. PubMed PMID: 32154192; PubMed Central PMCID: PMC7044152.
- Oron AP, Chao DL, Ezeanolue EE, et al. Caring for Africa’s sickle cell children: will we rise to the challenge? BMC Med. 2020;18(1):92. doi:https://doi.org/10.1186/s12916-020-01557-2 Epub 2020/04/29. doi: . PubMed PMID: 32340612; PubMed Central PMCID: PMC7187492
- Esposito S, Principi N. Impacts of the 13-valent pneumococcal conjugate vaccine in children. J Immunol Res. 2015;2015:591580. Epub 2015/09/10. doi: https://doi.org/10.1155/2015/591580. PubMed PMID: 26351648; PubMed Central PMCID: PMCPMC4553318.
- Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428–1433. doi:https://doi.org/10.1086/516781 Epub 2007/05/08. doi: . PubMed PMID: 17479937
- McCavit TL, Gilbert M, Buchanan GR. Prophylactic penicillin after 5 years of age in patients with sickle cell disease: a survey of sickle cell disease experts. Pediatr Blood Cancer. 2013;60(6):935–939; Epub 2012/11/30. doi: https://doi.org/10.1002/pbc.24395. PubMed PMID: 23193095;
- Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–1048. doi:https://doi.org/10.1001/jama.2014.10517 Epub 2014/09/10. doi: . PubMed PMID: 25203083
- Odey F, Okomo U, Oyo-Ita A. Vaccines for preventing invasive salmonella infections in people with sickle cell disease. Cochrane Database Syst Rev. 2018;12. CD006975. Epub 2018/12/07. doi: https://doi.org/10.1002/14651858.CD006975.pub4. PubMed PMID: 30521695; PubMed Central PMCID: PMC6517230. doi:
- Cannas G, Merazga S, Virot E. Sickle cell disease and infections in high- and low-income countries.Mediterr J Hematol Infect Dis.2019;11(1):e2019042; Epub 2019/07/17. doi: https://doi.org/10.4084/MJHID.2019.042. PubMed PMID: 31308918; PubMed Central PMCID: PMC6613623;
- Galadanci N, Wudil BJ, Balogun TM, et al. Current sickle cell disease management practices in Nigeria. Int Health. 2014;6(1):23–28. doi:https://doi.org/10.1093/inthealth/iht022 Epub 2013/10/12. doi: . PubMed PMID: 24114193; PubMed Central PMCID: PMC6281355
- Fernandes TA, Medeiros TM, Alves JJ, et al. Socioeconomic and demographic characteristics of sickle cell disease patients from a low-income region of northeastern Brazil. Rev Bras Hematol Hemoter. 2015;37(3):172–177. doi:https://doi.org/10.1016/j.bjhh.2015.03.013 Epub 2015/06/05. doi: . PubMed PMID: 26041419; PubMed Central PMCID: PMC4459435
- Bolarinwa RAAN, Aboderin OA, Durosinmi MA. The role of malaria in vaso-occlusive crisis of adult patients with sickle cell disease. J Med Med Sci. 2010;1:407–411.
- Oniyangi O, Omari AA. Malaria chemoprophylaxis in sickle cell disease. Cochrane Database Syst Rev. 2019;(11):PMID: 17054173.
- Ahmed SG. The role of infection in the pathogenesis of vaso-occlusive crisis in patients with sickle cell disease. Mediterr J Hematol Infect Dis. 2011;3(1):e2011028; Epub 2011/08/27. doi: https://doi.org/10.4084/MJHID.2011.028. PubMed PMID: 21869914; PubMed Central PMCID: PMC3152450;
- WHO. Sickle-cell disease: a strategy for the who African region report of the regional director. Malabo: Equatorial Guinea. 2010; Sixtieth Session:30.
- Diop S, Soudre F, Seck M, et al. Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial. Ann Hematol. 2011;90(1):23–27. doi:https://doi.org/10.1007/s00277-010-1040-z Epub 2010/08/10. doi: . PubMed PMID: 20694469
- Eke FU, Anochie I. Effects of pyrimethamine versus proguanil in malarial chemoprophylaxis in children with sickle cell disease: a randomized, placebo-controlled, open-label study. Curr Ther Res Clin Exp. 2003;64(8):616–625; Epub 2003/09/01. doi: https://doi.org/10.1016/j.curtheres.2003.09.003. PubMed PMID: 24944408; PubMed Central PMCID: PMC4053046;
- Serjeant G. Management of sickle cell disease: challenges and risks of transfusion. Int J Clin Transfusion Med. 2016;4:109–119.
- Ahmed SG, Bukar AA, Jolayemi B. Hematological indices of sickle cell anaemia patients with pulmonary tuberculosis in northern Nigeria. Mediterr J Hematol Infect Dis. 2010;2(1):e2010014; Epub 2010/01/01. doi: https://doi.org/10.4084/MJHID.2010.014. PubMed PMID: 21415951; PubMed Central PMCID: PMC3033109;
- Galadanci NA, Abdullahi SU, Ali Abubakar S, et al. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: final results of the SPIN trial. Am J Hematol. 2020;95(9):E247–E50. doi:https://doi.org/10.1002/ajh.25900 Epub 2020/06/09. doi: . PubMed PMID: 32510680
- Pantoja T, Opiyo N, Lewin S, et al. Implementation strategies for health systems in low-income countries: an overview of systematic reviews. Cochrane Database Syst Rev. 2017;9: CD011086. Epub 2017/09/13. doi: https://doi.org/10.1002/14651858.CD011086.pub2. CD011086. Epub 2017/09/13.
- Adewoyin AS. Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa). Anemia. 2015;2015:791498. Epub 2015/02/11. doi: https://doi.org/10.1155/2015/791498. PubMed PMID: 25667774; PubMed Central PMCID: PMC4312619.
- Adewoyin AS, Alagbe AE, Adedokun BO, et al. Knowledge, attitude and control practices of sickle cell disease among youth corps members in Benin City, Nigeria. Ann Ib Postgrad Med. 2015;13(2):100–107. Epub 2016/05/11. PubMed PMID: 27162522; PubMed Central PMCID: PMC4853875.
- Adeodu OO, Alimi T, Adekile AD. A comparative study of perception of sickle cell anaemia by married Nigeria rural and urban women. West Afr J Med. 2000;19(1):1–5. Epub 2000/05/23. PubMed PMID: 10821077.
- McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749–1758; Epub 2015/09/15. doi: https://doi.org/10.1517/14740338.2015.1088827. PubMed PMID: 26366626; PubMed Central PMCID: PMC5868345;
- Power-Hays A, Ware RE. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Curr Opin Hematol. 2020;27(3):172–180; Epub 2020/03/25. doi: https://doi.org/10.1097/MOH.0000000000000582. PubMed PMID: 32205588;
- Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403–408. doi:https://doi.org/10.1002/ajh.21699 Epub 2010/06/01. doi: . PubMed PMID: 20513116; PubMed Central PMCID: PMC2879711
- NIH. Evidence-based management of sickle cell disease: expert panel report. 2014.
- Adepoju P. Ghana takes on sickle-cell disease. Lancet. 2020;395(10222):402; Epub 2020/02/10. doi: https://doi.org/10.1016/S0140-6736(20)30293-2. PubMed PMID: 32035539;
- McGann PT, Williams TN, Olupot-Olupot P, et al. Realizing effectiveness across continents with hydroxyurea: enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. Am J Hematol. 2018;93(4):537–545. doi:https://doi.org/10.1002/ajh.25034 Epub 2018/01/11. doi: . PubMed PMID: 29318647; PubMed Central PMCID: PMC5870803
- Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell Anemia in Sub-Saharan Africa. N Engl J Med. 2019;380(2):121–131. doi:https://doi.org/10.1056/NEJMoa1813598 Epub 2018/12/07. doi: . PubMed PMID: 30501550; PubMed Central PMCID: PMC6454575
- Opoka RO, Ndugwa CM, Latham TS, et al. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017;130(24):2585–2593. doi:https://doi.org/10.1182/blood-2017-06-788935 Epub 2017/10/21. doi: . PubMed PMID: 29051184
- John CC, Opoka RO, Latham TS, et al. Hydroxyurea dose escalation for sickle cell Anemia in Sub-Saharan Africa. N Engl J Med. 2020;382(26):2524–2533. doi:https://doi.org/10.1056/NEJMoa2000146 Epub 2020/06/25. doi: . PubMed PMID: 32579813
- Abdullahi SU, Jibir BW, Bello-Manga H, et al. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022;9(1):e26–e37. doi:https://doi.org/10.1016/S2352-3026(21)00368-9 Epub 2022/01/01. doi: . PubMed PMID: 34971579
- Jain DL, Sarathi V, Desai S, et al. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.Hemoglobin.2012;36(4):323–332; Epub 2012/06/28. doi: https://doi.org/10.3109/03630269.2012.697948. PubMed PMID: 22734586;
- Patel DK, Mashon RS, Patel S, et al. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.Hemoglobin.2012;36(5):409–420; Epub 2012/08/14. doi: https://doi.org/10.3109/03630269.2012.709897. PubMed PMID: 22881992;
- Costa E, Tibalinda P, Sterzi E, et al. Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): how to meet major health needs at a reasonable cost. Am J Hematol. 2021;96(1):E2–E5. doi:https://doi.org/10.1002/ajh.26007 Epub 2020/09/26. doi: . PubMed PMID: 32974896; PubMed Central PMCID: PMC7756644
- Janyala S. CDSCO approves marketing of hydroxyurea tablets for sickle cell anemia treatment. The Indian Express. 2021 December 23. Available from: https://indianexpress.com/article/cities/hyderabad/cdsco-hydroxyurea-sickle-cell-anemia-treatment-7687532/.
- Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288–294. Epub 1998/02/07. PubMed PMID: 9414296.
- Adams RJ. Lessons from the stroke prevention trial in sickle cell Anemia (STOP) study. J Child Neurol. 2000;15(5):344–349; Epub 2000/06/01. doi: https://doi.org/10.1177/088307380001500511. PubMed PMID: 10830201;
- Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670. doi:https://doi.org/10.1016/S0140-6736(15)01041-7 Epub 2015/12/17. doi: . PubMed PMID: 26670617; PubMed Central PMCID: PMC5724392
- Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11. doi:https://doi.org/10.1056/NEJM199807023390102 Epub 1998/07/02. doi: . PubMed PMID: 9647873
- Enninful-Eghan H, Moore RH, Ichord R, et al. Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease.J Pediatr.2010;157(3):479–484; Epub 2010/05/04. doi: https://doi.org/10.1016/j.jpeds.2010.03.007. PubMed PMID: 20434165; PubMed Central PMCID: PMC2931594;
- Anie KA, Egunjobi FE, Akinyanju OO. Psychosocial impact of sickle cell disorder: perspectives from a Nigerian setting. Global Health. 2010;6(1):2; Epub 2010/02/23. doi: https://doi.org/10.1186/1744-8603-6-2. PubMed PMID: 20170540; PubMed Central PMCID: PMC2836308;
- Galadanci NA, Umar Abdullahi S, Vance LD, et al. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Am J Hematol. 2017;92(8):780–788. doi:https://doi.org/10.1002/ajh.24770 Epub 2017/04/26. doi: . PubMed PMID: 28439953; PubMed Central PMCID: PMC5523858
- Abdullahi SU , Jibir BW, Bello-Manga H, et al. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022;9(1): e26–e37. doi:https://doi.org/10.1016/S2352-3026(21)00368-9
- DeBaun MR, Jordan LC, King AA, et al. American society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554–1588. doi: https://doi.org/10.1182/bloodadvances.2019001142. Epub 2020/04/17. doi: . PubMed PMID: 32298430; PubMed Central PMCID: PMC7189278
- Ghafuri DL, Abdullahi SU, Dambatta AH, et al. Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: program Evaluation Using the RE-AIM Framework. J Pediatr Hematol Oncol. 2021. Epub 2021/05/19. doi: https://doi.org/10.1097/MPH.0000000000002179. Epub 2021/05/19.
- Idowu BO, Okedere TA. Diagnostic radiology in Nigeria: a country report. J Glob Radiol. 2020;6(1):1072.
- HA SGNH, Khan S. Nigeria country report: RAD-AID.org. 2015.
- Odame I, Jain D. Sickle cell disease: progress made & challenges ahead. Indian J Med Res. 2020;151(6):505–508; Epub 2020/07/29. doi: https://doi.org/10.4103/ijmr.IJMR_2064_20. PubMed PMID: 32719221; PubMed Central PMCID: PMC7602930;
- Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-Glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235. doi:https://doi.org/10.1056/NEJMoa1715971 Epub 2018/07/19. doi: . PubMed PMID: 30021096
- Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439. doi:https://doi.org/10.1056/NEJMoa1611770 Epub 2016/12/14. doi: . PubMed PMID: 27959701; PubMed Central PMCID: PMC5481200
- Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519. doi:https://doi.org/10.1056/NEJMoa1903212 Epub 2019/06/15. doi: . PubMed PMID: 31199090
- SE BP, Synnott PG, Chapman R, et al. Crizanlizumab Voxelotor, and L-Glutamine for sickle cell disease: effectiveness and value January 23, 2020. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_SCD_Evidence-Report_031220-FOR-PUBLICATION.PDF.
- Nnodu OE, Oron AP, Sopekan A, et al. Child mortality from sickle cell disease in Nigeria: a model-estimated, population-level analysis of data from the 2018 demographic and health survey.Lancet Haematol.2021;8(10):e723–e31; Epub 2021/09/06. doi: https://doi.org/10.1016/S2352-3026(21)00216-7. PubMed PMID: 34481551; PubMed Central PMCID: PMC8460996;
- Bank TW. Nigeria releases new report on poverty and inequality in country. May 28, 2020.
- Novartis. New Novartis medicine Adkveo (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease. Available from: https://www.novartis.com/news/media-releases/new-novartis-medicine-adakveo-crizanlizumab-approved-fda-reduce-frequency-pain-crises-individuals-living-sickle-cell-disease. [Accessed: November 15, 2019].
- Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: an update. Cytotherapy. 2018;20(7):899–910; Epub 2018/06/04. doi: https://doi.org/10.1016/j.jcyt.2018.04.003. PubMed PMID: 29859773; PubMed Central PMCID: PMC6123269;
- Broder MS, Quock TP, Chang E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10(7):366–374. Epub 2017/12/22. PubMed PMID: 29263771; PubMed Central PMCID: PMC5726064.
- Nature) LN. Screening saves lives, so why don’t governments fund it? Nature. 2021);596(7873):S6–S7.
- Perkin E. Battling sickle cell disease at its source. Available from: https://blog.perkinelmer.com/posts/battling-sickle-cell-disease-at-its-source/. [Accessed: March 25, 2019].
- (ASH). ASoH. consortium on newborn screening in Africa. Available frpm: https://www.hematology.org/global-initiatives/consortium-on-newborn-screening-in-africa#:~:text=The%20Consortium%20on%20Newborn%20Screening,)%20in%20sub%2DSaharan%20Africa.